Compare Lumen Technologies Inc (LUMN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Novartis AG — how do they compare? Lumen Technologies Inc trades at $6.39 (market cap $6.58B), while Novartis AG trades at $152.35 (market cap $295.37B). The key difference: Novartis AG is far larger — about 44.9× Lumen Technologies Inc's market cap, and Novartis AG pays a 3.07% dividend while Lumen Technologies Inc pays none. Which is the better fit depends on your goals.
| LUMN | NVS | |
|---|---|---|
Market Cap | $6.58B | $295.37B |
Sector | Media | Health |
52-Week High | $11.83 | $168.62 |
52-Week Low | $3.95 | $119.31 |
Enterprise Value | $18.20B | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LUMN trades at $6.33, down 4.67% today, with a bearish technical signal and neutral oscillators. Revenue declined to $12.40B in 2025, with a net loss of $1.74B, though Q2 2026 earnings beat estimates. The company is shifting to digital services, with strategic revenues growing 14.1% in Q2 2026. High debt of $17.49B remains a concern, but positive cash flow from operations of $4.74B in 2025 supports liquidity.
Outlook is mixed: analyst consensus price target is $7.67 with a hold-heavy rating, indicating cautious optimism. Risks include persistent revenue declines and heavy debt load, but opportunities lie in digital transformation and AI-driven growth. CEO share purchases and institutional holdings suggest insider confidence amid challenges.
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
